Trial Profile
A Phase II, Open-Label, Randomized, Multicenter Trial To Evaluate The Preliminary Safety And Efficacy of Hu1D10 [apolizumab] In Patients With Relapsed Or Refractory Grades I, II, or III B-Cell Non-Hodgkin's Lymphoma (Including Follicular, Small Lymphocytic And Marginal Zone/MALT [mucosa-associated lymphoid tissue])
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2009
Price :
$35
*
At a glance
- Drugs Apolizumab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Oct 2005 New trial record.